Biovalley > CD34 Antibody
CD34 Antibody
Brand : Aviva Systems Biology
| Datasheets/Manuals | Printable datasheet for CD34 Antibody |
|---|
| Predicted Species Reactivity | Human|Non-human Primate|Sheep |
|---|---|
| Product Format | Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
| Clonality | Monoclonal |
| Clone | 581 |
| Isotype | IgG1 |
| Host | Mouse |
| Conjugation | APC |
| Application | FC |
| Reconstitution and Storage | 2°C to 8°C |
| Purification | Purified by size-exclusion chromatography |
| Concentration | 10 ul / test |
| Specificity | The mouse monoclonal antibody 581 reacts with CD34 (Mucosialin), a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody recognizes the class III CD34 epitope resistant to neuraminidase, chymopapain and glycoprotease. HLDA V.; WS Code MA27 |
| Formulation | APC |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent. |
| Reference | Sanz E, Muñoz-A N, Monserrat J, Van-Den-Rym A, Escoll P, Ranz I, Alvarez-Mon M, de-la-Hera A: Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5925-30. Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, Richardson P, Benson R, Drayson M, Standen G, Vyas P, Freeman S: Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica. 2009 Aug;94(8):1160-3. Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T: Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery aftermyocardial infarction. Circulation. 2006 Mar 14;113(10):1311-25. Ninos JM, Jefferies LC, Cogle CR, Kerr WG: The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med. 2006 Feb 16;4:9. Ono F, Sharma BK, Smith CC, Burnett JW, Aurelian L: CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM).J Invest Dermatol. 2005 Jun;124(6):1215-24. Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A: CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normalbone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res. 2004 Nov 15;10(22):7599-606. Kato S, Ando K, Nakamura Y, Muguruma Y, Sato T, Yabe H, Yabe M, Hattori K, Yasuda Y, Hotta T: Absence of a CD34- hematopoietic precursor population in recipients of CD34+ stem cell transplantation. Bone Marrow Transplant. 2001 Sep;28(6):587-95. Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ: The adapter protein CrkL associates with CD34. Blood. 2001 Jun 15;97(12):3768-75. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montaño J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR: Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999 May 15;93(10):3379-90. And many other. Ando K, Nakamura Y, Chargui J, Matsuzawa H, Tsuji T, Kato S, Hotta T: Extensive generation of human cord blood CD34(+) stem cells from Lin(-)CD34(-) cells in a long-term in vitro system. Exp Hematol. 2000 Jun;28(6):690-9. |
|---|---|
| Gene Symbol | CD34 |
| Gene Full Name | CD34 molecule |
| Alias Symbols | CD34 antigen, hematopoietic progenitor cell antigen CD34. |
| NCBI Gene Id | 947 |
| Protein Name | Hematopoietic progenitor cell antigen CD34 |
| Description of Target | Possible adhesion molecule with a role in early hematopoiesis by mediating the attachment of stem cells to the bone marrow extracellular matrix or directly to stromal cells. Could act as a scaffold for the attachment of lineage specific glycans, allowing stem cells to bind to lectins expressed by stromal cells or other marrow components. Presents carbohydrate ligands to selectins. |
| Uniprot ID | P28906 |
| Protein Accession # | NP_001020280.1; NP_001764.1 |
| Nucleotide Accession # | NM_001025109.1; NM_001773.2 |
Protein interactions
| Name | # of Products |
|---|---|
| ATF5 | 17 |
| CHST4 | 5 |
| CREM | 35 |
| CRKL | 155 |
| PRKCD | 293 |
Biological pathways
| Name | # of Products |
|---|---|
| Cell adhesion | 1115 |
Biological process
| Name | # of Products |
|---|---|
| Cell adhesion | 446 |
| Cell motility | 13 |
| Cell proliferation | 293 |
| Cell-cell adhesion | 77 |
| Cellular response to heat | 26 |
| Cellular response to hypoxia | 44 |
| Endothelial cell proliferation | 15 |
| Endothelium development | 3 |
| Extracellular vesicular exosome assembly | 2 |
| Glomerular endothelium development | 5 |
| Glomerular filtration | 8 |
| Glutamate metabolic process | 14 |
| Hemopoiesis | 78 |
| Hemopoietic stem cell proliferation | 14 |
| Interleukin-2 secretion | 4 |
| Leukocyte migration | 113 |
| Mesangial cell-matrix adhesion | 2 |
| Metanephric glomerular mesangial cell differentiation | 1 |
| Negative regulation of blood coagulation | 15 |
| Negative regulation of gene expression | 70 |
| Negative regulation of necrotic cell death | 9 |
| Negative regulation of nitric oxide biosynthetic process | 16 |
| Negative regulation of tumor necrosis factor production | 35 |
| Paracrine signaling | 4 |
| Positive regulation of angiogenesis | 97 |
| Positive regulation of gene expression | 160 |
| Positive regulation of granulocyte colony-stimulating factor production | 3 |
| Positive regulation of interleukin-10 production | 32 |
| Positive regulation of odontogenesis | 11 |
| Positive regulation of transforming growth factor beta production | 5 |
| Positive regulation of vasculogenesis | 2 |
| Regulation of blood pressure | 59 |
| Regulation of immune response | 89 |
| Signal transduction | 1058 |
| Stem cell proliferation | 7 |
| Tissue homeostasis | 17 |
| Transdifferentiation | 5 |
| Vascular wound healing | 3 |
Cellular components
| Name | # of Products |
|---|---|
| Apical plasma membrane | 173 |
| Basal plasma membrane | 23 |
| Cytoplasm | 4549 |
| External side of plasma membrane | 261 |
| Extracellular region | 1573 |
| Glomerular endothelium fenestra | 1 |
| Integral to plasma membrane | 817 |
| Intercellular bridge | 3 |
| Lysosome | 161 |
| Membrane | 2769 |
| Perinuclear re | 2 |
Protein function
| Name | # of Products |
|---|---|
| Carbohydrate binding | 111 |
| Sulfate binding | 22 |
| Transcription factor binding | 934 |
-
CD34 Antibody - C-terminal region (ARP60993_P050)Catalog #: ARP60993_P050Species Tested: HumanApplication: IHC, WBFormat: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. -
CD34 Antibody - C-terminal region (ARP60994_P050)Catalog #: ARP60994_P050Species Tested: HumanApplication: WBFormat: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. -
CD34 Antibody (OABB00293)Catalog #: OABB00293Clone: PolyclonalSpecies Tested: Human, Mouse, RatApplication: FC, IHC-Fr, IHC-P, IPFormat: Lyophilized. Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3. -
CD34 ELISA Kit (Human) : 96 Wells (OKEH01394)Catalog #: OKEH01394Application: ELISA-SandwichKit Range: 0.156-10ng/mLSensitivity: 0.1 ng/mL



